CHICAGO, Oct. 14, 2016 – Optovue, the global leader in the development of optical coherence tomography (OCT) and OCT angiography (OCTA), will showcase its suite of advanced eye care technology at the American Academy of Ophthalmology Annual Meeting (AAO 2016) in Chicago, Oct. 15-18, in booth #944 at McCormick Place.
Specifically, the company will highlight the AngioVue™ Imaging System, a comprehensive platform with groundbreaking technology that provides clinicians with a non-invasive, dyeless technique for quickly visualizing vascular structures in the retina and choroid. The platform includes the recently introduced AngioVue Retina, which is configured with essential OCT and OCTA features designed for retinal practices. With AngioVue Retina, retinal specialists are able to assess new information about the microvasculature with extraordinary detail and obtain information that may be integrated with other diagnostic imaging results to form a complete picture of a patient's disease state and their treatment options. AngioVue Retina is the first OCTA system designed specifically for retina specialists.
Optovue is the first company to develop and commercialize the pioneering OCTA technology. Utilizing light rays to form detailed three-dimensional images of the retina, physicians are able to quickly visualize the blood flow. The AngioVue System produces a single image, derived from OCT data that complements fluorescein angiography (FA), but with a number of advantages. Unlike FA, AngioVue does not require the use of dye injections, and can be accomplished in a matter of seconds.
The company will also highlight DualTrac™ Motion Correction technology, a two-level approach to correcting motion artifacts resulting from patient movement, for use with both the AngioVue and AngioVue Retina systems. The first level provides real-time correction for rapid eye movements, blinking or eye drifting. The second level occurs during imaging post-processing and corrects smaller levels of motion distortion. This combined approach results in robust motion correction for patients who have trouble directing their focus on a central point during an eye exam, which is essential for high-quality OCTA imaging.
According to David Sarraf, M.D., Clinical Professor of Ophthalmology at the Jules Stein Eye Institute, UCLA, and his colleagues, DualTrac Motion Correction on the AngioVue system has improved the quality of images in most patients by correcting for naturally occurring motion artifact that result from blinking and involuntary eye movements called saccades.
"In my opinion, and based on my experience before and after installing the new tracking technology, the scans produce higher quality images, especially in patients with blinking that is not severe," said Dr. Sarraf. "Additionally, we have observed less motion artifact with small eye saccades. The DualTrac system allows patients to blink during image scanning and prevents multiple repeat scans, thereby facilitating the overall acquisition process in most patients."
Optovue, Inc. is a privately held medical device company founded in 2003. Headquartered in Fremont, Calif., the company is dedicated to the advancement and commercialization of high-speed OCT and OCTA technology used to facilitate the diagnosis and management of eye diseases, many of which may lead to permanent blindness. Optovue is the first company to develop and commercialize the pioneering OCTA technology. To date, there are over 190 peer-reviewed publications detailing the AngioVue Imaging System technology and clinical applications. The company has installed over 10,000 products worldwide and employs over 170 people. For more information, visit www.optovue.com.
# # #